VERTEX PHARMACEUTIC (VX1 BE) stock market data APIs
€390.0446
0(0%)
as of December 30, 2025
Try our APIs with
free plan!
VERTEX PHARMACEUTIC Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for VX1.BE.
Prev. Close
390.0446
Open
390.0446
High
390.0446
Low
390.0446
52 wk Range
312.45-471.4
Market Cap
46 841 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get VERTEX PHARMACEUTIC data using free add-ons & libraries
Get VERTEX PHARMACEUTIC Fundamental Data
VERTEX PHARMACEUTIC Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
VERTEX PHARMACEUTIC News
New
BofA unveils its top 10 U.S. ideas for Q1 2026
Investing.com -- Bank of America has released its new list of high-conviction U.S. stock ideas for the first quarter of 2026, featuring nine Buy-rated names and one Underperform. The quarterly lineup...
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know
Vertex Pharmaceuticals (VRTX) closed at $453.74 in the latest trading session, marking a -1.31% move from the prior day. This change lagged the S&P 500's daily loss of 0.14%. Meanwhile, the Dow experi...
Vertex Pharmaceuticals price target raised to $525 from $456 at Leerink
Leerink raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $525 from $456 and keeps an Outperform rating on the shares. The firm cites an increase in its terminal growth assumption f...
Should You Be Confident in Vertex Pharmaceuticals Incorporated’s (VRTX) Long-Term Outlook?
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
